JP7503063B2 - 神経変性疾患の治療のための２－フッ素化胆汁酸 - Google Patents

神経変性疾患の治療のための２－フッ素化胆汁酸 Download PDF

Info

Publication number
JP7503063B2
JP7503063B2 JP2021535715A JP2021535715A JP7503063B2 JP 7503063 B2 JP7503063 B2 JP 7503063B2 JP 2021535715 A JP2021535715 A JP 2021535715A JP 2021535715 A JP2021535715 A JP 2021535715A JP 7503063 B2 JP7503063 B2 JP 7503063B2
Authority
JP
Japan
Prior art keywords
compound
dihydroxy
difluoro
general formula
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021535715A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022514401A (ja
JP2022514401A5 (https=
Inventor
チャールズ ウェイマウス‐ウイルソン アレクサンダー
ジャン ポル リンクラウ ブルーノ
パッカー ゲマ
ワッツ ジョセフ
モルティボーイズ ヘザー
バンドマン オリバー
ヘイスティングス クリストファー
Original Assignee
エヌゼットピー ユーケー リミテッド
ザ ユニバーシティー オブ サウサンプトン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エヌゼットピー ユーケー リミテッド, ザ ユニバーシティー オブ サウサンプトン filed Critical エヌゼットピー ユーケー リミテッド
Publication of JP2022514401A publication Critical patent/JP2022514401A/ja
Publication of JP2022514401A5 publication Critical patent/JP2022514401A5/ja
Application granted granted Critical
Publication of JP7503063B2 publication Critical patent/JP7503063B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021535715A 2018-12-20 2019-12-20 神経変性疾患の治療のための２－フッ素化胆汁酸 Active JP7503063B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1820887.6 2018-12-20
GBGB1820887.6A GB201820887D0 (en) 2018-12-20 2018-12-20 Compounds
PCT/GB2019/053665 WO2020128514A1 (en) 2018-12-20 2019-12-20 2-fluorinated bile acids for the treatment of neurodegenerative diseases

Publications (3)

Publication Number Publication Date
JP2022514401A JP2022514401A (ja) 2022-02-10
JP2022514401A5 JP2022514401A5 (https=) 2022-12-13
JP7503063B2 true JP7503063B2 (ja) 2024-06-19

Family

ID=65364420

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021535715A Active JP7503063B2 (ja) 2018-12-20 2019-12-20 神経変性疾患の治療のための２－フッ素化胆汁酸

Country Status (15)

Country Link
US (1) US20220073557A1 (https=)
EP (1) EP3898645B1 (https=)
JP (1) JP7503063B2 (https=)
KR (1) KR102856276B1 (https=)
CN (1) CN113330020B (https=)
AU (1) AU2019411556B2 (https=)
BR (1) BR112021011189A2 (https=)
CA (1) CA3123333A1 (https=)
EA (1) EA202191521A1 (https=)
ES (1) ES3036094T3 (https=)
GB (1) GB201820887D0 (https=)
IL (1) IL284093B2 (https=)
MX (1) MX2021007551A (https=)
SG (1) SG11202105465WA (https=)
WO (1) WO2020128514A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4486318A4 (en) * 2022-03-02 2026-02-25 Boyce Thompson Institute For Plant Res Inc Cysteamides, related therapeutic compositions and associated processes
GB202208151D0 (en) 2022-06-01 2022-07-13 Nzp Uk Ltd Compounds
GB202314563D0 (en) 2023-09-22 2023-11-08 Nzp Uk Ltd Compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103333216A (zh) 2013-06-04 2013-10-02 苏州大学 5α-6-酮-胆甾烷类似物及其应用
WO2020025942A1 (en) 2018-07-30 2020-02-06 NZP UK Limited Fluorinated bile acid derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ298567A (en) * 1994-11-23 2000-01-28 Cocensys Inc Androstane and pregnane derivatives, pharmaceutical compositions and methods of treatment
WO1998005337A1 (en) * 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
FR2934596B1 (fr) * 2008-07-30 2015-04-10 Trophos Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation
ITMI20121344A1 (it) * 2012-07-31 2014-02-01 Erregierre Spa Processo di preparazione di acido ursodesossicolico ad elevata purezza
WO2014036377A1 (en) 2012-08-31 2014-03-06 Metselex Methods of promoting cell viability
US20150112089A1 (en) 2013-10-22 2015-04-23 Metselex, Inc. Deuterated bile acids
US11072630B2 (en) * 2015-03-10 2021-07-27 Metselex, Inc. Fluorinated and alkylated bile acids

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103333216A (zh) 2013-06-04 2013-10-02 苏州大学 5α-6-酮-胆甾烷类似物及其应用
WO2020025942A1 (en) 2018-07-30 2020-02-06 NZP UK Limited Fluorinated bile acid derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorg. Med. Chem. Lett.，2014年，24，1222-1227

Also Published As

Publication number Publication date
IL284093B1 (en) 2025-03-01
EP3898645C0 (en) 2025-06-25
AU2019411556A1 (en) 2021-06-10
WO2020128514A1 (en) 2020-06-25
IL284093A (en) 2021-08-31
EP3898645B1 (en) 2025-06-25
GB201820887D0 (en) 2019-02-06
KR20210125982A (ko) 2021-10-19
EP3898645A1 (en) 2021-10-27
CN113330020A (zh) 2021-08-31
ES3036094T3 (en) 2025-09-12
BR112021011189A2 (pt) 2021-08-31
JP2022514401A (ja) 2022-02-10
AU2019411556B2 (en) 2025-04-03
MX2021007551A (es) 2021-10-13
EA202191521A1 (ru) 2021-09-10
IL284093B2 (en) 2025-07-01
CN113330020B (zh) 2024-04-05
CA3123333A1 (en) 2020-06-25
US20220073557A1 (en) 2022-03-10
SG11202105465WA (en) 2021-06-29
KR102856276B1 (ko) 2025-09-05

Similar Documents

Publication Publication Date Title
JP6896113B2 (ja) ジアザ二環式置換イミダゾピリミジンおよび呼吸障害を治療するためのその使用
JP6999639B2 (ja) 置換ジアザヘテロ－二環式化合物およびそれらの使用
JP6518270B2 (ja) Ｇｓｋ−３阻害剤としての新規チアジアゾリジンジオン
JP7503063B2 (ja) 神経変性疾患の治療のための２－フッ素化胆汁酸
JP7241807B2 (ja) １５β－ヒドロキシ－酢酸オサテロンの結晶多形
CN114805478A (zh) 氘代拟肽类化合物及其用途
JP2015525239A (ja) 新規カベルゴリン誘導体
CN113272298A (zh) 用于治疗呼吸系统疾病的化合物和组合物
KR20190134722A (ko) 치료 화합물 및 방법
CN103717583B (zh) 二苯并硫氮杂*衍生物及其在治疗中枢神经系统紊乱中的用途
CN102947300B (zh) 生物碱氨基酯衍生物及其药物组合物
CN102947298B (zh) 生物碱氨基酯衍生物及其药物组合物
JP2005527518A (ja) 新規なカルコン（ｃｈａｌｃｏｎｅ）誘導体とその使用
CN116514902A (zh) 氘代拟肽类化合物及其用途
JP2025518741A (ja) ミトコンドリア機能関連疾患治療用の３－アザステロイド化合物
ES2465005T3 (es) Derivado de óxido de benzotiofeno y sus sales
HU215153B (hu) Eljárás indolszármazékok és e vegyületeket tartalmazó gyógyászati készítmények előállítására
EA046372B1 (ru) 2-фторированные желчные кислоты для лечения нейродегенеративных заболеваний
HK40062202A (en) 2-fluorinated bile acids for the treatment of neurodegenerative diseases
HK40062202B (en) 2-fluorinated bile acids for the treatment of neurodegenerative diseases
CN113620967B (zh) 一种α-倒捻子素衍生物及其制备方法和应用
CN104011043B (zh) 作为抗毒蕈碱剂的1-氮杂杂环基乙酸的奎宁环酯、它们的制备方法及其药用组合物
CN117285566A (zh) 一种膦酸酯类化合物及其医药用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240321

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240514

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240607

R150 Certificate of patent or registration of utility model

Ref document number: 7503063

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150